BioSpace News Archive

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced financial results for the first half of the fiscal year ended June 30, 2022.

OncoOne announced the appointment of three new members to its scientific advisory board to accelerate the clinical development of the company’s oxidized macrophage migration inhibitory factor -targeting pipeline.

BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, announced topline results from an investigator-Sponsored Phase 2 clinical trial of NE3107 for the treatment of Alzheimer’s Disease.

Gerresheimer AG and Stevanato Group S.p.A. announce that they have jointly developed a high-end Ready-To-Use solution platform with an initial focus on vials, based on Stevanato Group’s market-leading EZ-fill® technology.

Stevanato Group S.p.A. and Gerresheimer AG announce that they have jointly developed a high-end Ready-To-Use solution platform with an initial focus on vials, based on Stevanato Group’s market-leading EZ-fill® technology.

IRLAB Therapeutics AB announced that Richard Godfrey, CEO of IRLAB, will present at Pareto Securities’ 13th Annual Healthcare Conference in Stockholm, Sweden, on Thursday, September 8, 2022, at 11:00 am CEST.

Orbital Therapeutics launched with a vision of enhancing global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible.

GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the results from phase I study of GFH018 (TGF-β R1 inhibitor) monotherapy (NCT05051241) for treatment of advanced solid tumor will be presented as a poster at the 2022 European Society for Medical Oncology Meeting in Paris on September 12th.

VetCor announced that it has acquired People, Pets, & Vets, a leading veterinary services company with over 150 animal hospitals located throughout the United States.

Compugen Ltd. announced , that Yaron Turpaz, Ph.D., Senior Vice President and Senior Advisor, Computational Discovery at Compugen will participate in a panel at the Fierce Biotech Summit taking place from 20 to 21 September 2022, in Boston, United States.